Your browser doesn't support javascript.
loading
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild, Axel; Ascierto, Paolo A; Schadendorf, Dirk; Grob, Jean Jacques; Ribas, Antoni; Kiecker, Felix; Dutriaux, Caroline; Demidov, Lev V; Lebbé, Céleste; Rutkowski, Piotr; Blank, Christian U; Gutzmer, Ralf; Millward, Michael; Kefford, Richard; Haas, Tomas; D'Amelio, Anthony; Gasal, Eduard; Mookerjee, Bijoyesh; Chapman, Paul B.
Afiliação
  • Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany. Electronic address: ahauschild@dermatology.uni-kiel.de.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale," Naples, Italy.
  • Schadendorf D; University Hospital of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
  • Grob JJ; Aix-Marseille University, Marseille, France.
  • Ribas A; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Kiecker F; Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Dutriaux C; Hôpital Saint-André, Bordeaux, France.
  • Demidov LV; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Lebbé C; APHP Dermatology and CIC Department, Hôpital Saint-Louis, INSERM U976, University Paris Diderot, Paris, France.
  • Rutkowski P; Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
  • Blank CU; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Gutzmer R; Hannover Medical School, Hannover, Germany.
  • Millward M; University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Kefford R; Westmead Hospital and Macquarie University, Sydney, NSW, Australia.
  • Haas T; Novartis Pharma AG, Basel, Switzerland.
  • D'Amelio A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Mookerjee B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Chapman PB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eur J Cancer ; 125: 114-120, 2020 01.
Article em En | MEDLINE | ID: mdl-31864178
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Neoplasias Cutâneas / Dacarbazina / Proteínas Proto-Oncogênicas B-raf / Imidazóis / Melanoma / Antineoplásicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Neoplasias Cutâneas / Dacarbazina / Proteínas Proto-Oncogênicas B-raf / Imidazóis / Melanoma / Antineoplásicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido